Published in Am Heart J on July 01, 1999
French Observatory on the Management of Cardiogenic Shock in 2016 (FRENSHOCK) | NCT02703038
Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation (2001) 2.22
The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther (2007) 1.61
Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc (2010) 1.51
Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev (2009) 1.40
Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5. Heart Fail Rev (2010) 1.24
Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res (2007) 1.13
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev (2009) 1.02
β₂ AR agonists in treatment of chronic heart failure: long path to translation. J Mol Cell Cardiol (2010) 1.00
Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA (2006) 0.98
Chronic inotropic therapy in end-stage heart failure. Am Heart J (2006) 0.98
Comparing three life-limiting diseases: does diagnosis matter or is sick, sick? J Pain Symptom Manage (2011) 0.97
Chronic intermittent hypoxia increases left ventricular contractility in C57BL/6J mice. J Appl Physiol (1985) (2009) 0.95
Adrenergic signaling in heart failure: a balance of toxic and protective effects. Pflugers Arch (2014) 0.94
Right ventricular adaptation and failure in pulmonary arterial hypertension. Can J Cardiol (2015) 0.94
Long-term intravenous inotropes in low-output terminal heart failure? Clin Res Cardiol (2016) 0.90
Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin. Clin Res Cardiol (2015) 0.90
The influence of heart failure self-care on health outcomes: hypothetical cardioprotective mechanisms. J Cardiovasc Nurs (2009) 0.90
Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail Rev (2013) 0.90
Hospital patterns of use of positive inotropic agents in patients with heart failure. J Am Coll Cardiol (2012) 0.90
Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure. Med Sci Monit (2014) 0.84
Adenylyl cyclase type 5 in cardiac disease, metabolism, and aging. Am J Physiol Heart Circ Physiol (2013) 0.83
Classical inotropes and new cardiac enhancers. Heart Fail Rev (2007) 0.83
Abnormal Ca(2+) cycling in failing ventricular myocytes: role of NOS1-mediated nitroso-redox balance. Antioxid Redox Signal (2014) 0.83
Management of the cardiorenal syndrome in decompensated heart failure. Cardiorenal Med (2014) 0.82
SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope. Br J Pharmacol (2014) 0.82
Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance. Front Biosci (Landmark Ed) (2009) 0.81
Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension. Circulation (2014) 0.80
Cardiac contractility modulation therapy in advanced systolic heart failure. Nat Rev Cardiol (2013) 0.80
Electrical modalities beyond pacing for the treatment of heart failure. Heart Fail Rev (2011) 0.80
Inotropes do not increase mortality in advanced heart failure. Int J Gen Med (2014) 0.79
Newer treatments for decompensated heart failure: focus on levosimendan. Drug Des Devel Ther (2009) 0.79
The interface between monitoring and physiology at the bedside. Crit Care Clin (2015) 0.78
Probenecid as a noninjurious positive inotrope in an ischemic heart disease murine model. J Cardiovasc Pharmacol Ther (2012) 0.78
Beta blockers as anti-arrhythmic agents. Heart Fail Rev (2004) 0.78
Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus. J Cardiovasc Pharmacol (2014) 0.77
Heart failure: chapter 8. Treatment of end-stage heart failure. Neth Heart J (2004) 0.77
Diagnosing and managing acute heart failure in the emergency department. Clin Exp Emerg Med (2015) 0.75
Decompensated heart failure. Einstein (Sao Paulo) (2013) 0.75
β2-adrenoreceptor Inverse Agonist Down-regulates Muscarine Cholinergic Subtype-3 Receptor and Its Downstream Signal Pathways in Airway Smooth Muscle Cells in vitro. Sci Rep (2017) 0.75
Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and etiology. J Card Fail (2014) 0.75
Inotropic agents use in patients hospitalized with acute decompensated heart failure: a retrospective analysis from a 22-year registry in a Middle-Eastern Country (1991-2013). BMC Cardiovasc Disord (2016) 0.75
Authors' reply concerning the letter by Ensminger et al. Clin Res Cardiol (2015) 0.75
Phospholamban Ablation Using CRISPR/Cas9 System Improves Mortality in a Murine Heart Failure Model. PLoS One (2016) 0.75
Response and tolerance to oral vasodilator up-titration after intravenous vasodilator therapy in advanced decompensated heart failure. Eur J Heart Fail (2015) 0.75
Clinical Characteristics and Treatment of Cardiomyopathies in Children. Curr Cardiol Rev (2016) 0.75
Self-Care for the Prevention and Management of Cardiovascular Disease and Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association. J Am Heart Assoc (2017) 0.75
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA (1996) 17.62
Evaluating the yield of medical tests. JAMA (1982) 14.05
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med (1993) 7.19
Regression modelling strategies for improved prognostic prediction. Stat Med (1984) 7.09
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med (1994) 6.78
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med (1997) 6.19
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med (1996) 5.94
Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? N Engl J Med (1997) 5.80
Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J (2001) 5.77
Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med (1993) 5.59
Outcome of acute myocardial infarction according to the specialty of the admitting physician. N Engl J Med (1996) 5.51
A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol (1989) 5.50
Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis (2006) 5.20
Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med (2001) 4.85
Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet (1981) 4.75
Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet (2000) 4.54
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53
Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation (2003) 4.48
Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med (1995) 4.37
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med (1995) 4.29
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
The management of hypertrophic cardiomyopathy. N Engl J Med (1997) 4.15
1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol (1999) 4.15
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation (1996) 4.01
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med (1995) 3.69
Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol (1997) 3.64
Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med (1991) 3.63
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 3.61
Referral patterns for coronary artery disease treatment: gender bias or good clinical judgment? Ann Intern Med (1992) 3.39
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation (1995) 3.38
Scorecard cardiovascular medicine. Its impact and future directions. Ann Intern Med (1994) 3.32
Ultrasound-assisted cannulation of the internal jugular vein. A prospective comparison to the external landmark-guided technique. Circulation (1993) 3.31
Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation (2002) 3.22
Job strain and the prevalence and outcome of coronary artery disease. Circulation (1995) 3.22
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 3.20
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation (1996) 3.14
Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Circulation (1998) 3.11
The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med (1995) 3.08
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. JAMA (1992) 3.06
Mannheim intima-media thickness consensus. Cerebrovasc Dis (2004) 3.05
A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med (1987) 3.04
Side effects of long-term amiodarone therapy. Circulation (1983) 3.03
Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet (2001) 3.02
Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.97
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol (2000) 2.89
Psychological factors related to prehospital delay during acute myocardial infarction. Circulation (1991) 2.88
Clinical data bases. Accomplishments and unrealized potential. Med Care (1985) 2.83
Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med (1996) 2.83
ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol (1996) 2.81
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J (2003) 2.78
Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J (2004) 2.73
Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol (1990) 2.67
Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet (2002) 2.61
Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. J Am Coll Cardiol (1988) 2.59
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53
Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med (1997) 2.52
Factors affecting sensitivity and specificity of exercise electrocardiography. Multivariable analysis. Am J Med (1984) 2.49
Cardiac fatigue following prolonged endurance exercise of differing distances. Med Sci Sports Exerc (2000) 2.47
Production of arrhythmias by elevated carboxyhemoglobin in patients with coronary artery disease. Ann Intern Med (1990) 2.45
Cardiogenic shock complicating acute coronary syndromes. Lancet (2000) 2.42
Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol (1983) 2.34
Electrocardiographic changes in 1000 highly trained junior elite athletes. Br J Sports Med (1999) 2.32
Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. Lancet (1997) 2.30
Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial. JAMA (2001) 2.29
Randomized comparison of a strategy of predischarge coronary angiography versus exercise testing in low-risk patients in a chest pain unit: in-hospital and long-term outcomes. J Am Coll Cardiol (2001) 2.27
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem (1998) 2.27
Expression of inducible nitric oxide synthase in human heart failure. Circulation (1996) 2.26
Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med (1986) 2.26
A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications. J Am Coll Cardiol (1999) 2.24
Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J (1999) 2.24
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 2.23
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol (1999) 2.23
Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart (2004) 2.22
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J (1985) 2.22
Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol (1992) 2.18
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J (1997) 2.16